{"nctId":"NCT00990184","briefTitle":"Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)","startDateStruct":{"date":"2009-09"},"conditions":["Impaired Fasting Glucose","Prediabetes"],"count":21,"armGroups":[{"label":"Colesevelam Hydrochloride","type":"EXPERIMENTAL","interventionNames":["Drug: Colesevelam","Other: placebo"]}],"interventions":[{"name":"Colesevelam","otherNames":["colesevelam HCl"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males or females (postmenopausal, surgically sterile or using double-barrier method of contraception), aged 18-75 years, FPG 100-115 mg/dl at screening (average of 2 measurements during screening; no individual measurement outside of the range 92-125 mg/dl)\n* In good health as determined by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis\n* HbA1c \\<6.5% at screening\n* Body mass index (BMI) in the range of 22-40 kg/m2 inclusive and with a stable (+/-2.5 kg) weight for the last 6 months\n* Subjects must be willing to:\n\n  * Maintain prior exercise and dietary habits throughout the study\n  * Comply with all study requirements\n  * Provide written informed consent\n\nExclusion Criteria:\n\n* Pregnant or lactating females\n* Patients diagnosed with type 2 diabetes or that have taken glucose-lowering agents or insulin, except during pregnancy\n* Chronic oral or parenteral corticosteroid treatment (\\>7 consecutive days of treatment) within 8 weeks prior to screening\n* HIV protease inhibitors\n* Warfarin or phenytoin use\n* Triglycerides \\>500 mg/dl\n* History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection\n* History of dysphagia, swallowing disorders or intestinal motility disorder\n* History of pancreatitis\n* Uncontrolled hypothyroidism\n* Individuals with clinical hepatic disease or liver function tests greater than ≥2 times upper limits of normal within 30 days preceding the first dose of study drug\n* On a weight loss program with ongoing weight loss, or starting an intensive exercise program within 4 weeks of study initiation\n* Current or prior (within the past 3 months) treatment with a bile acid sequestrant (colesevelam, colestipol, colestimide, or cholestyramine)\n* Use of any investigational drug in the last 30 days\n* Donation of one unit (500 ml) or more of blood, significant blood loss equaling at least one unit of blood within the past 2 weeks or a blood transfusion within 8 weeks prior to screening\n* Employment by the research center","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Acute Insulin Response (AIRg) to Intravenous Glucose","description":"Increase in insulin following glucose injection. AIRg is measured as the magnitude of the insulin response to an intravenous glucose injection calculated over the 10 minutes following glucose administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1866","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1752","spread":null}]}]}]},{"type":"SECONDARY","title":"Insulin Sensitivity","description":"Tissue response to circulating insulin in the blood. Insulin sensitivity is measured using a mathematical model that quantifies the fractional rate of change in glucose concentrations per unit of insulin. Low values are insulin resistant and high values are insulin sensitive. \\*Please note: the \"-1\" in the Unit of Measure should be a superscripted value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"0.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Glucose Disappearance Rate","description":"Rate of fall of glucose in the blood","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.32","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.26","spread":"0.08"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":21},"commonTop":["Constipation","Cholelithiasis"]}}}